Enclomiphene vs TRT: Two Different Paths, Compared

Enclomiphene and TRT are two different paths to the same goal of raising low testosterone, and the difference is mechanistic: testosterone replacement therapy (TRT) supplies testosterone from outside the body, while enclomiphene prompts your own body to make more by acting on the pituitary. That single distinction drives most of the practical tradeoffs, especially around fertility, where enclomiphene generally preserves it and standard TRT tends to suppress it. Both are prescription-level decisions; TRT is FDA-approved for hypogonadism, while enclomiphene is used off-label and is not FDA-approved. This is education, not medical advice, and which path fits is your clinician's call.

The core difference: replace versus stimulate

Everything else follows from how each option works.

TRT delivers exogenous testosterone, meaning testosterone made outside your body, typically by intramuscular or subcutaneous injection, transdermal gel, or implanted pellet. Your blood testosterone rises because you are adding the hormone directly. Our TRT basics guide covers what that involves day to day.

Enclomiphene takes the opposite approach. It is the trans-isomer of clomiphene, a selective estrogen receptor modulator (SERM). By blocking estrogen's negative feedback at the hypothalamus, it lifts the brakes on the system: the brain releases more GnRH, the pituitary releases more LH and FSH, and the testes respond by producing more of your own testosterone. In other words, enclomiphene does not replace testosterone, it stimulates the body to make it.

That is why the fertility outcomes diverge so sharply. Standard TRT suppresses LH and FSH, which suppresses sperm production. Enclomiphene raises LH and FSH, so it generally preserves and can even support fertility. We go deeper on that mechanism in our TRT and fertility article.

Side-by-side comparison

The table compares the two approaches across the dimensions that actually shape the decision. It describes mechanisms and tradeoffs, not doses, which a provider sets individually.

Factor	TRT (injectable testosterone)	Enclomiphene (off-label)
Mechanism	Supplies exogenous testosterone	Stimulates your own production via LH and FSH
Effect on fertility	Suppresses sperm production	Preserves, and may improve
FDA status	Approved for hypogonadism	Not FDA-approved; used off-label
Administration	Injection, gel, or pellet	Oral capsule
Testosterone response	Reliable, titrated to labs	Variable; depends on pituitary and testicular function
Works best for	Primary or secondary hypogonadism	Secondary hypogonadism (intact, responsive pituitary)
Testicular atrophy	Possible; hCG can be added to mitigate	Not expected
Long-term safety data	Extensive	Limited

The pattern in the table is the takeaway: TRT trades fertility and natural-axis function for reliability and a deep evidence base, while enclomiphene trades some of that reliability and evidence for fertility preservation and an oral, axis-friendly mechanism.

The FDA status nuance you must understand

This is the part where marketing often outruns the facts, so it is worth being precise.

Enclomiphene is not FDA-approved. It was developed as a product called Androxal, but development was discontinued after the manufacturer did not complete the required Phase 3 studies, and a Complete Response Letter was issued in 2015. The program was later formally discontinued. There is no FDA-approved enclomiphene product on the market.

What exists in 2026 is widespread off-label use. Physicians can legally prescribe enclomiphene off-label, and compounding pharmacies can produce it under the 503A framework, and telehealth providers have expanded access to compounded enclomiphene. That is legal, but legal off-label use is not the same as FDA approval, and the distinction matters: an approved drug has cleared the agency's bar for safety and efficacy in a defined indication, while off-label compounded enclomiphene has not. Any article or clinic that implies enclomiphene is "approved" is wrong on the facts.

TRT, by contrast, uses FDA-approved testosterone products and is an approved treatment for diagnosed hypogonadism, with testosterone classified as a Schedule III controlled substance requiring a prescription.

What the evidence shows

Published randomized data, including work in Reproductive Biology and Endocrinology, indicates that enclomiphene can raise testosterone into the normal range while preserving LH and FSH, which is the fertility-friendly result it is prized for. So the short-term mechanism and effect are reasonably well understood.

The honest limits: study sizes have generally been small, and long-term comparative safety data against TRT is limited. The fact that enclomiphene never secured FDA approval reflects, in part, that the evidence package did not meet the regulatory bar, not that it has been proven unsafe, but the gap is real. TRT, having been used and studied for decades, simply has a deeper long-term evidence base. A 2026 position statement from the British Society for Sexual Medicine, published in the World Journal of Men's Health, reflects the ongoing clinical effort to define enclomiphene's role.

Who each path tends to suit

Neither option is universally better; the fit depends on the diagnosis and the person.

Enclomiphene tends to be considered by men with secondary hypogonadism, where the testes can still respond but the upstream signal is low, who want to preserve fertility, prefer an oral medication, or want to avoid shutting down their natural production. It cannot help primary hypogonadism, where the testes themselves cannot respond, because no amount of LH and FSH stimulation will move a gland that cannot answer.

TRT tends to be the path when reliable, titratable testosterone is the priority, when fertility is not a concern or is being managed separately, or when the hypogonadism is primary. For men on TRT who still want to protect fertility, hCG can be added, which is its own conversation covered in our fertility and hCG guide.

Both paths aim at improving the symptoms and body-composition effects of low testosterone. On the body-composition front, neither is a shortcut: as with any approach, training and nutrition remain the primary drivers, a theme we cover for medication-assisted change in fat loss versus muscle loss.

Primary versus secondary hypogonadism: the deciding variable

If there is one clinical fact that settles whether enclomiphene is even an option, it is the type of hypogonadism, so it is worth understanding the distinction.

Primary hypogonadism means the problem is in the testes themselves: they cannot produce adequate testosterone even when the brain is sending strong LH and FSH signals. In that situation, enclomiphene cannot help, because it works by increasing those upstream signals, and shouting louder at a gland that cannot respond changes nothing. TRT is the path that works for primary hypogonadism, since it supplies the testosterone the testes cannot make.

Secondary hypogonadism means the testes are capable, but the upstream signaling from the hypothalamus and pituitary is low, so the testes are simply not being told to work. This is the scenario where enclomiphene shines, because restoring the LH and FSH signal can prompt the responsive testes back into production. This is precisely why LH and FSH appear on the baseline lab panel: they help a clinician sort primary from secondary, which in turn shapes whether stimulating the natural axis is even feasible. Our bloodwork guide covers why those markers are drawn up front.

Administration and lifestyle differences

Beyond mechanism, the day-to-day experience of each option differs in ways that genuinely affect adherence.

Enclomiphene is an oral capsule, which appeals to people who dislike needles or simply prefer the simplicity of a daily pill. There is no injection technique to learn, no sharps to dispose of, and no site rotation to manage. For some men, that convenience is a real factor in choosing it.

TRT, in its common injectable form, requires learning injection technique, managing supplies, and rotating sites, though many people find the routine straightforward within a few weeks, and the longer-acting esters mean injections are not daily. TRT also comes in non-injectable forms like gels and pellets, which trade the needle for other tradeoffs such as daily application or a minor in-office procedure. None of these logistics should drive the medical decision on their own, but they are legitimate quality-of-life considerations that a provider will factor in alongside the clinical picture.

The monitoring both paths share

Whichever route is chosen, both require ongoing bloodwork, and that is easy to overlook when enclomiphene is marketed as the simpler option. Enclomiphene users still need their testosterone, LH, FSH, and estradiol tracked to confirm the medication is producing the intended response and to watch for the estrogen-related effects a SERM can cause. TRT users need the fuller monitoring panel, including hematocrit and PSA, because supplying exogenous testosterone carries its own set of risks to watch.

In other words, neither path is "set it and forget it." Both are provider-directed therapies with lab monitoring built in, and the choice between them does not change the fundamental requirement that a licensed clinician oversees the protocol over time.

What to ask a provider

Useful questions for a clinician include: Is my low testosterone primary or secondary, and does that rule either option in or out? How important is fertility to me now and in the future? Am I comfortable with an off-label, non-FDA-approved medication, and what does that mean for monitoring? And how will we track whether the chosen path is actually working? Those answers require confirmed labs, which is why bloodwork comes before any decision.

The tracking angle

Whether you end up on injectable TRT or oral enclomiphene, the protocol only works if it is followed and measured. Myo logs doses, whether that is an injection or a daily capsule, and trends the testosterone and supporting lab values that tell you and your provider whether the chosen path is doing its job. It keeps that data in one reviewable place for follow-up visits. Myo tracks a provider-directed protocol; it does not prescribe, source medication, or decide which path is right for you.

References

• Hims. Is enclomiphene FDA-approved? Educational overview of Androxal development and discontinuation. hims.com.
• Reproductive Biology and Endocrinology. Published data on enclomiphene raising testosterone while preserving LH and FSH.
• World Journal of Men's Health. British Society for Sexual Medicine position statement on enclomiphene, 2026.
• Endocrine Society. Testosterone Therapy in Men With Hypogonadism: Clinical Practice Guideline. endocrine.org.